Metformina + Sitagliptina Yrik

Metformin and Sitagliptin, the active ingredients in Metformina + Sitagliptina Yrik, are a Biguanide and a DPP‑4 inhibitor presented as a tablet for oral use. They are prescribed to improve blood‑glucose control in adults with type 2 diabetes mellitus.

GNH USA supplies Metformina + Sitagliptina Yrik as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina Yrik is used in the management of type 2 diabetes mellitus, acting on multiple glucose‑regulating pathways.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels and reduces HbA1c when added to diet and exercise. - Inadequate control on metformin alone: provides additional glycaemic reduction as part of combination therapy. - Adjunct to insulin therapy: helps achieve target glucose levels while allowing lower insulin doses.

Metformina + Sitagliptina Yrik may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache. - Hypoglycaemia (when used with sulfonylureas or insulin): dizziness, sweating. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic acidosis, muscle pain, rapid breathing. - Pancreatitis: upper abdominal pain radiating to the back, nausea, vomiting. - Severe allergic reaction: rash, swelling, difficulty breathing. - Hepatic failure: jaundice, dark urine, fatigue. - Acute kidney injury: reduced urine output, swelling. - Cardiovascular events: chest pain, palpitations.

Before initiating Metformina + Sitagliptina Yrik, clinicians should consider several safety aspects.

- Renal function assessment: avoid or adjust dose in patients with impaired renal function. - Hepatic disease evaluation: use with caution in liver disease due to lactic acidosis risk. - Alcohol consumption: limit intake as it may increase lactic acidosis risk. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Concomitant medications: monitor for hypoglycaemia when combined with insulin or sulfonylureas. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Metformina + Sitagliptina Yrik can interact with several drug classes. Awareness of major and moderate interactions helps minimise adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and lactic acidosis. - Phenformin or other biguanides: combined use increases risk of lactic acidosis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise sitagliptin plasma levels. - Alcohol excess: synergistic effect on lactic acidosis risk.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened risk of hypoglycaemia; dose adjustment may be needed. - Diuretics (especially thiazides): may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Beta‑blockers: may mask hypoglycaemia symptoms. - Rifampin: may reduce sitagliptin exposure, decreasing efficacy.